BiomX Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BiomX Inc. on July 29, 2024, regarding an event that occurred on July 23, 2024. The filing addresses the Company's status with the NYSE American LLC concerning its continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes and Listing Status
- Deficiency Notice: On May 23, 2024, the Company received a deficiency letter from the NYSE American for non-compliance with Sections 1003(a)(i), (ii), and (iii) of the Company Guide.
- Plan Acceptance: On July 23, 2024, the NYSE American accepted the Company's plan to regain compliance.
- Compliance Deadline: The Company has been granted a "Plan Period" until November 23, 2025, to regain compliance with the listing standards.
- Trading Status: The Common Stock (Symbol: PHGE) and Units (Symbol: PHGE.U) will continue to be listed and traded on the NYSE American during the Plan Period, subject to other listing requirements.
Outlook, Risks, and Contingencies
The Company intends to take all reasonable measures to regain compliance by the November 23, 2025 deadline. However, if the Company fails to regain compliance by that date or does not make sufficient progress consistent with the Plan during the Plan Period, the NYSE American may initiate delisting proceedings. The filing includes a Safe Harbor statement noting that forward-looking statements regarding the expectation to regain compliance are subject to inherent uncertainties and risks.
Investor Verification Checklist
- Verify the specific details of the compliance plan submitted to the NYSE American.
- Monitor periodic reviews by the NYSE American regarding the Company's progress during the Plan Period.
- Review the "Risk Factors" section in the Company's Annual Report on Form 10-K (filed April 4, 2024) for a comprehensive list of risks.
- Confirm the Company's stock price and market capitalization to assess the likelihood of meeting the specific financial metrics required for Sections 1003(a)(i), (ii), and (iii).